Physician profile
Yasser Jamal
NPI 1588873236
$1,399.58
in general payments reported to CMS, 2019-2025
20 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.10 · 2023: $431 · 2024: $443 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Education: $14.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.01 |
| Education | $14.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.83 | 2023-2025 | |
| Janssen Biotech, INC. | $107.75 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Boston Scientific Corporation | $61.34 | 2023-2025 | Watchman Flx |
| Sandoz INC. | $44.94 | 2023 | Hyrimoz |
| Pfizer INC. | $41.06 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.16 | 2024 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $32.95 | 2025 | |
| Phathom Pharmaceuticals, INC. | $32.64 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $30.53 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $28.50 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.74 | 2023 | Rebyota |
| Celgene Corporation | $21.51 | 2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2023 | |
| Lilly USA, LLC | $19.85 | 2025 | Omvoh |
| Redhill Biopharma INC. | $19.84 | 2023 | Talicia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $15.71 | 2023 | Suflave |
| Madrigal Pharmaceuticals | $15.16 | 2024 | Resmetirom |
| Enterra Medical, INC. | $14.81 | 2024 | |
| Merck Sharp & Dohme LLC | $13.99 | 2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $13.89 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.